As reported by a phase I/II trial (NCT02178722), a novel combined therapy of epacadostat (IDO1 inhibitor) and pembrolizumab (PD-1 inhibitor) was well tolerated and showed antitumor activity in patients with triple-negative breast cancer [55]. The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.